Topamax in the treatment of epilepsy
Gromov, S.A.; Lipatova, L.V.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 105(5): 28-31
2005
ISSN/ISBN: 1997-7298 PMID: 15952537 Document Number: 590491
To specify efficacy of topamax in different types of epileptic seizures and its influence on patient's quality of life (QL), the drug was assigned to 38 patients, aged 18-69 years, as mono- and polytherapy (in combination with other anticonvulsive medications). Topamax dosages ranged from 25-50 mg at a base-line to 600 mg. Treatment duration was 6-18 months. Positive effect of different extent was achieved in 95,7 % patients. A seizures frequency decreased by 25% in 17,4% patients; by 50% - in 8,7%; by 75% - in 43,5%; a complete disappearance of seizures was detected in 30,4%. The results confirmed the earlier data received by the authors that topamax was most effective in generalized convulsive, partial and secondary generalized seizures. It exerts a less pronounced effect in myoclonic seizures and absences. After topamax treatment, a total QL index measured by WHO questionnaire increased by 5,2%. The drug is well tolerated and does not affect cognitive functions of the patients. It is concluded that currently topamax is one of the most effective antiepileptic medications.